These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 8635461)

  • 1. Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide.
    Schoneberg T; Yun J; Wenkert D; Wess J
    EMBO J; 1996 Mar; 15(6):1283-91. PubMed ID: 8635461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
    Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
    Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.
    Oksche A; Schülein R; Rutz C; Liebenhoff U; Dickson J; Müller H; Birnbaumer M; Rosenthal W
    Mol Pharmacol; 1996 Oct; 50(4):820-8. PubMed ID: 8863826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reconstitution of mutant V2 vasopressin receptors by adenovirus-mediated gene transfer. Molecular basis and clinical implication.
    Schöneberg T; Sandig V; Wess J; Gudermann T; Schultz G
    J Clin Invest; 1997 Sep; 100(6):1547-56. PubMed ID: 9294123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus.
    Tsukaguchi H; Matsubara H; Taketani S; Mori Y; Seido T; Inada M
    J Clin Invest; 1995 Oct; 96(4):2043-50. PubMed ID: 7560098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin receptor mutations causing nephrogenic diabetes insipidus.
    Bichet DG; Turner M; Morin D
    Proc Assoc Am Physicians; 1998; 110(5):387-94. PubMed ID: 9756088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.
    Robben JH; Knoers NV; Deen PM
    Am J Physiol Renal Physiol; 2005 Aug; 289(2):F265-72. PubMed ID: 16006591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Truncated V2 vasopressin receptors as negative regulators of wild-type V2 receptor function.
    Zhu X; Wess J
    Biochemistry; 1998 Nov; 37(45):15773-84. PubMed ID: 9843382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. V2 vasopressin receptor dysfunction in nephrogenic diabetes insipidus caused by different molecular mechanisms.
    Schöneberg T; Schulz A; Biebermann H; Grüters A; Grimm T; Hübschmann K; Filler G; Gudermann T; Schultz G
    Hum Mutat; 1998; 12(3):196-205. PubMed ID: 9711877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the vasopressin V2 receptor gene in families with nephrogenic diabetes insipidus and functional expression of the Q-2 mutant.
    Rosenthal W; Seibold A; Antaramian A; Gilbert S; Birnbaumer M; Bichet DG; Arthus MF; Lonergan M
    Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):429-36. PubMed ID: 7920187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs/adenylyl cyclase system.
    Birnbaumer M; Gilbert S; Rosenthal W
    Mol Endocrinol; 1994 Jul; 8(7):886-94. PubMed ID: 7984150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional characterization of novel loss-of-function mutations in the vasopressin type 2 receptor gene causing nephrogenic diabetes insipidus.
    Böselt I; Tramma D; Kalamitsou S; Niemeyer T; Nykänen P; Gräf KJ; Krude H; Marenzi KS; Di Candia S; Schöneberg T; Schulz A
    Nephrol Dial Transplant; 2012 Apr; 27(4):1521-8. PubMed ID: 21917732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [From genes to disease: from vasopressin-V2-receptor and aquaporine-2 to nephrogenic diabetes insipidus].
    Knoers NV; Deen PM
    Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2402-4. PubMed ID: 11145096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrogenic diabetes insipidus.
    Bichet DG
    Adv Chronic Kidney Dis; 2006 Apr; 13(2):96-104. PubMed ID: 16580609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
    Robben JH; Sze M; Knoers NV; Deen PM
    Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.
    Bernier V; Morello JP; Zarruk A; Debrand N; Salahpour A; Lonergan M; Arthus MF; Laperrière A; Brouard R; Bouvier M; Bichet DG
    J Am Soc Nephrol; 2006 Jan; 17(1):232-43. PubMed ID: 16319185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular biological studies on patients with nephrogenic diabetes insipidus].
    Szalai C; Molnár E; Sallay P; Czinner A
    Orv Hetil; 1998 Apr; 139(15):883-7. PubMed ID: 9579101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular aspects of vasopressin receptor function.
    Schöneberg T; Kostenis E; Liu J; Gudermann T; Wess J
    Adv Exp Med Biol; 1998; 449():347-58. PubMed ID: 10026824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopressin receptor mutations in nephrogenic diabetes insipidus.
    Bichet DG
    Semin Nephrol; 2008 May; 28(3):245-51. PubMed ID: 18519085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The property of a novel v2 receptor mutant in a patient with nephrogenic diabetes insipidus.
    Inaba S; Hatakeyama H; Taniguchi N; Miyamori I
    J Clin Endocrinol Metab; 2001 Jan; 86(1):381-5. PubMed ID: 11232028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.